Adipose tissue inflammation: a main driver of metabolic dysfunction-associated steatohepatitis-Immunometabolism-CSCIED科技核心评价数据库-手机版

Adipose tissue inflammation: a main driver of metabolic dysfunction-associated steatohepatitis

Adipose tissue inflammation: a main driver of metabolic dysfunction-associated steatohepatitis

ES评分 0 浏览量：276 下载量：0

DOI	10.1097/IN9.0000000000000082
刊名	Immunometabolism IJ
年，卷(期)	2026, 8(2)
作者	Vachliotis, Ilias D.; Polyzos, Stergios A.,
作者单位	Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
摘要	This viewpoint focuses on core evidence regarding the cross-talk between adipose tissue inflammation and hepatic inflammation that possibly leads to the progression of metabolic dysfunction–associated steatotic liver disease to metabolic dysfunction–associated steatohepatitis, hepatic fibrosis, and cirrhosis. It is highlighted that the adipose tissue and hepatic inflammation increase in parallel with insulin resistance, possibly affecting each other, thereby leading to advanced liver disease. This interplay is partly mediated via adipokines produced by the adipose tissue, hepatokines produced by the liver, and cytokines produced by the immune cells infiltrating both the adipose tissue and the liver.
Abstract	This viewpoint focuses on core evidence regarding the cross-talk between adipose tissue inflammation and hepatic inflammation that possibly leads to the progression of metabolic dysfunction–associated steatotic liver disease to metabolic dysfunction–associated steatohepatitis, hepatic fibrosis, and cirrhosis. It is highlighted that the adipose tissue and hepatic inflammation increase in parallel with insulin resistance, possibly affecting each other, thereby leading to advanced liver disease. This interplay is partly mediated via adipokines produced by the adipose tissue, hepatokines produced by the liver, and cytokines produced by the immune cells infiltrating both the adipose tissue and the liver.
关键词	adipokines; cytokines; hepatokines; inflammation; insulin resistance; metabolic dysfunction–associated steatohepatitis; metabolic dysfunction–associated steatotic liver disease
KeyWord	adipokines; cytokines; hepatokines; inflammation; insulin resistance; metabolic dysfunction–associated steatohepatitis; metabolic dysfunction–associated steatotic liver disease
基金项目
页码	-

参考文献
相关文献

[1]. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97.

[2]. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-47.

[3]. Graupera I, Thiele M, Castera L, et al.; LiverScreen Consortium Investigators. Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study. Lancet. 2026;407(10537):1448-58.

[4]. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia. 2024;67(11):2375-92.

[5]. Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42(2):92-108.

[6]. Guan Y, Kim Y, Wang Y, et al. Adipocyte death promotes hepatic infiltration of S100A8+ macrophages and steatotic liver disease progression in mice. J Clin Invest. 2025;135(21):e190635.

[7]. Rohm TV, Dos Reis FCG, Rocha KCE, et al. Adipose tissue macrophages in metabolic dysfunction-associated steatohepatitis secrete extracellular vesicles that activate liver fibrosis in obese male mice. Gastroenterology. 2025;169(4):691-704.e9.

[8]. Caviglia GP, Casalone E, Rosso C, et al. Extracellular vesicles miRNome profiling reveals miRNAs engagement in dysfunctional lipid metabolism, chronic inflammation and liver damage in subjects with metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2025;62(1):22-32.

[9]. Boesch M, Lindhorst A, Feio-Azevedo R, et al. Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH. J Hepatol. 2024;80(3):397-408.

[10]. Madsen JD, Dam TV, Nambiar J, et al. Adipose tissue cell states linked to progression and clinical subtypes of MASLD in human obesity. bioRxiv. Preprint posted online September 29, 2025. doi: 10.1101/2025.09.25.678284.

[11]. Kountouras J, Kazakos E, Kyrailidi F, et al. Innate immunity and nonalcoholic fatty liver disease. Ann Gastroenterol. 2023;36(3):244-56.

[12]. Huang G, Li D. The macrophage opera: from metabolic prolog to oncogenic crescendo in metabolic dysfunction-associated steatotic liver disease. Front Med (Lausanne). 2026;13:1751290.

[13]. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1062-79.

[14]. Moon HS, Dalamaga M, Kim SY, et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34(3):377-412.

[15]. Polyzos SA, Kountouras J. AdipoRon exerts divergent effects on hepatic and bone metabolism. Diabetes Obes Metab. 2026;28(1):787-8.

[16]. Frühbeck G, Gómez-Ambrosi J. Rationale for the existence of additional adipostatic hormones. FASEB J. 2001;15(11):1996-2006.

[17]. Frühbeck G, Gómez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia. 2003;46(2):143-72.

[18]. Gusev E, Sarapultsev A, Zhuravleva Y. Insulin resistance and inflammation. Int J Mol Sci . 2026;27(3):1237.

[19]. Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J Hepatol. 2023;78(5):1048-62.

[20]. Maria Barbalho S, Laurindo LF, Valenti VE, et al. Organokine-mediated crosstalk: a systems biology perspective on the pathogenesis of MASLD-A narrative review. Int J Mol Sci . 2025;26(23):11547.

[21]. Pezzino S, Puleo S, Luca T, et al. Adipokine and hepatokines in metabolic dysfunction-associated steatotic liver disease (MASLD): current and developing trends. Biomedicines. 2025;13(8):1854.

[22]. Filimidou I, Orfanidou M, Goulas A, et al. Circulating fibroblast growth factor-21 in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Curr Obes Rep. 2025;14(1):51.

[23]. Raptis DD, Mantzoros CS, Polyzos SA. Fibroblast growth factor-21 as a potential therapeutic target of nonalcoholic fatty liver disease. Ther Clin Risk Manag. 2023;19:77-96.

[24]. Doulberis M, Papadimitriou K, Papaefthymiou A, et al. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine. 2020;1(4):170-83.

[25]. He Y, Chen Y, Qian S, et al. Immunopathogenic mechanisms and immunoregulatory therapies in MASLD. Cell Mol Immunol. 2025;22(10):1159-77.

[26]. Zafer M, Tavaglione F, Romero-Gómez M, et al. Review article: GLP-1 receptor agonists and glucagon/GIP/GLP-1 receptor dual or triple agonists-mechanism of action and emerging therapeutic landscape in MASLD. Aliment Pharmacol Ther. 2025;61(12):1872-88.

[27]. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089-99.

[28]. Francque SM, Bedossa P, Ratziu V, et al.; NATIVE Study Group. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547-58.

[29]. Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism. 2016;65(9):1297-306.

[30]. Polyzos SA, Targher G. Hepatic thyroid hormone receptor-β signalling: mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis. Diabetes Obes Metab. 2025;27(4):1635-47.

引用本文

Vachliotis, Ilias D.; Polyzos, Stergios A.. Adipose tissue inflammation: a main driver of metabolic dysfunction-associated steatohepatitis [J]. Immunometabolism. 2026; 8; (2). - .

文献评论

相关学者

相关机构